CXCR2 and asthma: Using in vitro angiogenesis assay, angiogenesis antibody array, enzyme linked immunosorbent assay (ELISA) and a competitive CXCR2-selective antagonist, this study demonstrates that BSMC derived from asthma patients exhibit increased angiogenic potential compared to controls that is mediated by CXCR2-ligands.